Abstract B039: APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumors
Antoine Simoneau(Io Therapeutics (United States)), Teng Teng(Beijing Wuzi University), Hsin‐Jung Wu(Tango Therapeutics (United States)), Tenzing Khendu(Tango Therapeutics (United States)), Jannik N. Andersen(Tango Therapeutics (United States)), Douglas A. Whittington(Amgen (United States)), Yi Yu(Novartis (United States)), Shangtao Liu(Tango Therapeutics (United States)), Ashley H Choi(Io Therapeutics (United States)), Binzhang Shen(Tango Therapeutics (United States)), Samuel R. Meier, Hannah Stowe(Massachusetts General Hospital), Hongxiang Zhang(Huazhong Agricultural University), Serge Gueroussov(Io Therapeutics (United States)), Gwen Cusing(Io Therapeutics (United States)), Steven Lombardo(Io Therapeutics (United States))
Cited by 2